Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Yuan Yang, Ping Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5753.

https://doi.org/10.1182/blood-2024-204870

Published: 2024

Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2024-207269

Published: 2024

Journal Articles

The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Hematologic Malignancies

Hua Xue, Jiangbo Zhang, Jing Wang, Songying Zhao, Huimei Guo, Jia Liu, Jianmei Xu, Yao Liu

Blood (2024) 144 (Supplement 1): 5025.

https://doi.org/10.1182/blood-2024-202234

Published: 2024

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Blood (2024) 144 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2024-208159

Published: 2024

Journal Articles

Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study

Hua Xue, Jianmei Xu, Jing Wang, Songying Zhao, Huimei Guo, Jiangbo Zhang, Jia Liu, Yao Liu

Blood (2024) 144 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2024-200174

Published: 2024

Journal Articles

A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI

Hua Xue, Yan Su, Jianmei Xu, Jiangbo Zhang, Songying Zhao, Jing Wang, Huimei Guo, Jia Liu, Yao Liu

Blood (2024) 144 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2024-206921

Published: 2024

Journal Articles

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2024-205802

Published: 2024

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Song Jin, Lingzhi Yan, Jingjing Shang, Weiqin Yao, Xiaolan Shi, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2024-209260

Published: 2024

Journal Articles

Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR αβ -Depleted Haplo-HSCT

Huaying Liu, Dejun Chen, Jing Wang, Simeng Lv, Yuelin He, Wing Leung, Chunfu Li

Blood (2024) 144 (Supplement 1): 4941.

https://doi.org/10.1182/blood-2024-205593

Published: 2024

Journal Articles

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Lingzhi Yan, Xiaolan Shi, Jing Wang, Song Jin, Ying Yao, Panfeng Wang, Jingjing Shang, Yingying Zhai, Shuang Yan, Yun Xu, Jiajia Meng, Weiqin Yao, Xiao Ma, Chengcheng Fu, Depei Wu

Blood (2024) 144 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2024-205595

Published: 2024

Journal Articles

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2024-205492

Published: 2024

Journal Articles

Therapeutic Efficacy Analysis of 16 Patients with Primary Systemic Light Chain Amyloidosis Predominantly Exhibiting Advanced Cardiac Amyloidosis

Hua Xue, Jing Wang, Shaojie Ye, Huimei Guo, Songying Zhao, Jia Liu, Jiangbo Zhang, Jianmei Xu, Yao Liu

Blood (2024) 144 (Supplement 1): 7830.

https://doi.org/10.1182/blood-2024-204139

Published: 2024

Journal Articles

Dual-Risk Adjusted Therapy for Elderly Patients with Multiple Myeloma Based on Dynamic Frailty Assessment and R-ISS: A Prospective Clinical Trial

Hua Xue, Jianmei Xu, Jie Li, Xiaohui Suo, Haisheng Liu, Juan Wang, Jing Wang, Songying Zhao, Huimei Guo, Yao Liu

Blood (2024) 144 (Supplement 1): 7057.

https://doi.org/10.1182/blood-2024-200398

Published: 2024

Journal Articles

Multiparametric Flow Cytometry Combined with Multi-Mutated Genes Measurable Residual Disease Assessed By Droplet Digital PCR to Predict Relapse in Acute Myeloid Leukemia Patients: A Single Center Experience

Hua Xue, Shaojie Ye, Huimei Guo, Jianmei Xu, Xi Su, Lin Wang, Jiangbo Zhang, Jia Liu, Songying Zhao, Jing Wang, Yao Liu

Blood (2024) 144 (Supplement 1): 6166.

https://doi.org/10.1182/blood-2024-201879

Published: 2024

Journal Articles

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Lingli Wang, Jinjie Gao, Wei Wan, Fei Dong, Jing Wang, Weilong Zhang, Ping Yang, Lan Ma, Wei Zhao, Jijun Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6340.

https://doi.org/10.1182/blood-2024-205570

Published: 2024

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Chunyuan Li, Jinjie Gao, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6339.

https://doi.org/10.1182/blood-2024-205068

Published: 2024

Journal Articles

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Ping Yang, Chunyuan Li, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6338.

https://doi.org/10.1182/blood-2024-205042

Published: 2024

Journal Articles

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Xiaoyu Hao, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2024-204938

Published: 2024

NARROW

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Hematologic Malignancies

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study

A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR αβ -Depleted Haplo-HSCT

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Therapeutic Efficacy Analysis of 16 Patients with Primary Systemic Light Chain Amyloidosis Predominantly Exhibiting Advanced Cardiac Amyloidosis

Dual-Risk Adjusted Therapy for Elderly Patients with Multiple Myeloma Based on Dynamic Frailty Assessment and R-ISS: A Prospective Clinical Trial

Multiparametric Flow Cytometry Combined with Multi-Mutated Genes Measurable Residual Disease Assessed By Droplet Digital PCR to Predict Relapse in Acute Myeloid Leukemia Patients: A Single Center Experience

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only